Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: Five-year results of a prospective randomized study

Cancer

Volumn 77, Issue 12, 1996, Pages 2560-2566

  Galligioni, Enzo ^a   Quaia, Michele ^a   Merlo, Alberto ^b   Carbone, Antonino ^a   Spada, Antonella ^a   Favaro, Daniela ^a   Santarosa, Manuela ^a   Sacco, Cosimo ^a   Talamini, Renato ^a   Francini, Marcello ^c   Crivellari, Diana ^c   Di Donna, Domenico ^c   Mazza, Giorgio ^c   Viggiano, Giuseppe ^c   Galassi, Paola ^c   Panizzo, Roberto ^c   Carmignani, Giorgio ^c   Fiaccavento, Caspare ^c  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b Ospedale Civile   (Italy)

^c Centro di Riferimento Oncologico ^*

Author keywords

Active specific immunotherapy; Adjuvant therapy; Delayed type cutaneous hypersensitivity; Renal cancer

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOSE TIME EFFECT RELATION; FEMALE; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; TUMOR CELL; ULCER;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; BCG VACCINE; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0030006748     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960615)77:12<2560::AID-CNCR20>3.0.CO;2-P     Document Type: Article

References (34)

1. Boring CC, Squires TS, Tong T. Cancer statistics: 1993. CA Cancer J Clin 1993;43:7-26.
2. Decarli A, La Vecchia C, Negri E, Cislaghi C. Cancer mortality in Italy, 1989, and an overview of trends from 1955 to 1989. Tumori 1993;79:151-65.
3. Stenzl A, deKernion JB. Pathology, biology, and clinical staging of renal cell carcinoma. Semin Oncol 1989;16:3-11.
4. Thrasher JB, Paulson DF. Prognostic factors in renal cancer. In: Olsson CA, Sawczuk IS, editors. The urologic clinics of North America. Volume 20, Number 2. Philadelphia: WB Saunders, 1993:247-62.
5. Pizzocaro G, Piva L, Di Fronzo G, Giongo A, Cozzoli A, Dormia E, et al. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol 1987;138:1379-81.
6. Davis M. Renal cell carcinoma. Semin Oncol Nursing 1993;9:267-71.
7. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1893-1993. Semin Oncol 1995;22:42-60.
8. Chan RC. Renal cell carcinoma. In: Fletcher GH, editor. Textbook of radiotherapy. Philadelphia: Lea & Febiger 1980:919-21.
9. Stahl M, Wilke H-J, Seeber S, Schmoll HJ. Cytokines and cytotoxic agents in renal cell carcinoma: a review. Semin Oncol 1992;19:70-9.
10. Stadler WM, Vogelzang NJ. Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma. Sem in Oncol 1995;22:67-73.
11. Parkinson DR, Sznol M. High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma. Semin Oncol 1995;22:61-6.
12. McCune CS, O'Donnell RW, Marquis DM, Sahasrabudhe DM. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol Immunother 1990;32:62-6.
13. Berd D, Maguire HC Jr., McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 1990;8:1858-67.
14. Bystryn JC, Oratz R, Roses D, Harris M, Henn M, Lew R. Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 1992;69:1157-64.
15. Mitchell MS, Harel W, Kempf RA, Hu E, Kan-Mitchell J, Boswell WD, et al. Active specific immunotherapy for melanoma. J Clin Oncol 1990;8:856-69.
16. Hanna MG Jr., Brandhorst JS, Peters LC. Active specific immunotherapy of residual micrometastasis: an evaluation of sources, doses and ratios of BCG to tumor cells. Cancer Immunol Immunother 1979;7:65-73.
17. Hoover HC Jr., Peters LC, Brandhorst JS, Hanna MG Jr. Therapy for spontaneous metastases with an autologous tumor vaccine in a guinea pig model. J Surg Res 1981;30:409-15.
18. Hoover HC Jr., Brandhorst JS, Peters LC, Surdike MG, Takeshita Y, Madariaga J, et al. Adjuvant specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a Phase III prospectively randomized trial. J Clin Oncol 1993;11:390-9.
19. Hoover HC Jr., Surdike MG, Dangel RB, Peters LC, Hanna MG Jr. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 1985;55:1236-43.
20. Peters LC, Brandhorst JS, Hanna MG Jr. Preparation of immunotherapeutic autologous tumor cell vaccine form solid tumors. Cancer Res 1979;39:1353-60.
21. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
22. Siminovitch JP, Montie J, Straffon RA. Lymphadenectomy in renal adenocarcinoma. J Urol 1982;127:1090-1.
23. Novick A. Current surgical approaches, nephron-sparing surgery, and the role of surgery in integrated immunologic approach to renal-cell carcinoma. Semin Oncol 1995;22:29-33.
24. Hermanek P, Schrott KM. Evaluation of the new tumor, nodes and metastases classification of renal cell carcinoma. J Urol 1990;144:238-42.
25. Hoover HC Jr., Surdike M, Dangel RB, Peters LC, Hanna MG Jr. Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guèrin vaccine. Cancer Res 1984;44:1671-6.
26. Hoover HC Jr., Hanna MG Jr. Immunotherapy by active specific immunization: clinical applications. In: De Vita VT Jr., Hellman S, editors. Biologic therapy of cancer. Philadelphia: JB Lippincott, 1991:670-82.
27. Hanna MG Jr., De Jager R, Guinan P, Crispen R, Lamm D, Khanna O, et al. Bacillus Calmette-Guèrin (BCG) vaccine for tubercolosis: antitumor effect in experimental animals and humans. Vaccine Res 1992;1(2):69-91.
28. Robinson MRG. The experience with intravesical BCG-immunotherapy in the management of superficial bladder cancer in the United States. EORTC Genitourinary Group Monograph 1989;6:147-52.
29. Grange JM, Stanford JL, Rook GAW. Tubercolosis and cancer: parallels in host responses and therapeutic approaches? Lancet 1995;345:1350-2.
30. Ransom JH, Pelle B, Hanna MG Jr. Expression of class II major histocompatibility complex molecules correlates with human colon tumor vaccine efficacy. Cancer Res 1992; 52:3460-6.
31. Ransom JH, Pelle BA, Brandhorst JS, Hoover HC Jr., Vermorken JB, Avis FP, et al. HLA-DR and ICAM-I expression on human colon carcinoma vaccines predicts clinical response to active specific immunotherapy. Vaccine Res 1993;2(2):65-78.
32. Santarosa M, Favaro D, Quaia M, Spada A, Sacco C, Talamini R, et al. Expression and release of intercellular adhesion molecule-1 in renal cancer patients. Int J Cancer 1995; 62:271-5.
33. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987;316:898-905.
34. Rosenberg SA. Immunotherapy with recombinant cytokines and activated lymphokines in patients with advanced cancer: review of surgery branch, NCI experience. In: Salmon ES, editor. Adjuvant therapy of cancer. 6th edition. Philadelphia: WB Saunders, 1990:33-42.